Avrobio, Inc., a Cambridge, MA-based clinical-stage biotechnology company developing gene therapies for rare diseases and cancer, raised $25m in Series A financing.
The round was co-led by Atlas Venture, Clarus and SV Life Sciences. In conjunction with AVROBIO’s Series A financing, Bruce Booth, DPhil, Partner at Atlas Venture, will serve as Chairman of the Board of Directors. Also joining the Board are Scott Requadt, Managing Director at Clarus, and Joshua Resnick, MD, Partner at SV Life Sciences.
The company intends to use the funds to accelerate development of its clinical stage programs in Fabry disease and acute myeloid leukemia (AML), and to expand its pipeline in rare diseases and solid and liquid cancers.
Led by Geoff MacKay, President and Chief Executive Officer, Avrobio develops lentiviral-based gene therapies that have the potential to transform patients’ lives in a single dose. The company is focused on the development of its Phase 1 programs in Fabry disease and acute myeloid leukemia (AML), while actively building a pipeline of therapies to treat other rare diseases, and solid and liquid cancers.
Avrobio also has offices in Toronto, ON.